AlphAIAlphAI — Financial news for AI agents
tradingview.comNOV 42 min read$UTHR

United Therapeutics Revenue Rises 4% to $832.5 Million in Third Quarter

United Therapeutics reported Q3 2026 revenue of $832.5M, up 4% YoY. Net income fell 24% to $258.6M, with EPS at $5.71. Operating income was $307.8M. Tyvaso DPI sales grew, while Nebulized Tyvaso declined due to competition. The company also acquired Thymmune Therapeutics and invested in R&D for organ alternatives and cardiopulmonary treatments.

Original reporting
tradingview.com
Published Nov 4, 2026, 11:33 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
United Therapeutics Revenue Rises 4% to $832.5 Million in Third Quarter — source image
Source · tradingview.com
Decision brief

The 30-second read

$UTHRBearishMed
01

Why it matters

Earnings highlight revenue growth but margin compression, influencing short‑term price action.

02

Market read

First report of United Therapeutics' Q3 results; material for biotech investors.

03

What to watch

Potential upside from the recent acquisition of Thymmune Therapeutics and price increase on Tyvaso DPI.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Quarterly earnings release via SEC 8‑K filing.

Company-level read

Ticker impact

$UTHRBearishHigh confidence
Context

United Therapeutics disclosed Q3 2026 revenue, earnings and net income in its 8‑K filing.

Expected impact

likely downside as investors price in lower profitability

Evidence & confidence

Revenue rose only 4% while net income fell sharply, which may trigger a sell‑off.

Market effects

Sector

Biopharma sector may see modest pressure as a peer reports weaker earnings.

Regional

U.S. biotech stocks could experience slight pullback in early trading.

Global

Limited to investors tracking U.S. healthcare earnings.

Counterpoint

What could challenge this read

If the revenue beat expectations, the stock could rebound despite earnings decline.

Key entities

  • company
    United Therapeutics Corp

    Biopharma firm reporting Q3 2026 results.

Read at source← All news

StoryUnited Therapeutics reports Q3 2026 revenue up 4% to $832.5M, net income down 24%

Also covered by

4 outlets

Related articles

NOV 4
$UTHRMedAI 8/10

United Therapeutics Q3 2026 Revenue Up 4%, Net Income Falls 24%

United Therapeutics (UTHR) reported Q3 2026 revenue of $832.5M, up 4% YoY, but net income fell 24% to $258.6M due to higher R&D spending and competitive pressures. EPS declined 20% to $5.71. Tyvaso DPI sales rose 13%, while nebulized Tyvaso fell 12%. R&D expenses surged 119% to $279.2M, partly due to the Thymmune acquisition. The company repurchased shares under a 10b5-1 plan and a $2B repurchase program.

minichart.com.sg2 min
NOV 4
$UTHRHigh

United Therapeutics buys out Pfizer royalty for $525 million

United Therapeutics (UTHR) will pay $525M to Pfizer's Arena subsidiary to end royalty obligations on ralinepag, a drug for pulmonary arterial hypertension. The FDA is reviewing an application for oral ralinepag, with a decision expected by June 24, 2027. United Therapeutics acquired rights to ralinepag in 2018 and is also developing an inhaled version. According to the company, the transaction reflects confidence in the drug's revenue potential.

investing.com1 min